The GRACE study was funded by Tibotec Therapeutics.
Gilead Sciences provided emtricitabine, tenofovir disoproxil
fumarate, and emtricitabine/tenofovir disoproxil fumarate.
J.C. is supported in part by a grant from the National Institute
of Allergy and Infectious Diseases, National Institutes of
Health (K24 AI56933). We thank Samantha Taylor, Ph.D.,
Medicus International New York, for her editorial assistance.
Lori DeLaitsch of Tibotec Therapeutics Clinical Affairs reviewed
and provided input on this article. Editorial support
was funded by Tibotec Therapeutics.